Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
| Kat. Nr. | Arten | Produktbeschreibung | Struktur | Reinheit | Merkmal |
|---|---|---|---|---|---|
| AHG-Y69 | Mouse | Anti-Human IgG Antibody-Acridinium ester (MALS verified) |
|
||
| IGG-LY69 | Mouse | HRP conjugated Anti-Human-IgG-Fc Antibody (6F11C8), mAb |
Immobilized Human TNF-alpha Protein, His Tag (Cat. No. TNA-H5228) at 2 μg/mL (100 μL/well) can bind Human Monoclonal Anti-TNF-alpha antibody, Human IgG1 (16H5) (Cat. No. TNA-AM494) when detected by HRP conjugated Anti-Human-IgG-Fc Antibody (6F11C8),mAb (Cat. No. IGG-LY69) dilute at 1:10000 (0.0842μg/ml) (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Imlifidase | Mac-1 | Approved | Hansamed Inc | Idefirix | EU | Rejection of renal transplantation | Hansa Biopharma Ab | 2020-08-25 | Rejection of renal transplantation; Kidney Diseases; Purpura, Thrombotic Thrombocytopenic; Rejection of organ transplantation; Renal Insufficiency, Chronic; Guillain-Barre Syndrome; Kidney Failure, Chronic | Details |
| Imlifidase | Mac-1 | Approved | Hansamed Inc | Idefirix | EU | Rejection of renal transplantation | Hansa Biopharma Ab | 2020-08-25 | Rejection of renal transplantation; Kidney Diseases; Purpura, Thrombotic Thrombocytopenic; Rejection of organ transplantation; Renal Insufficiency, Chronic; Guillain-Barre Syndrome; Kidney Failure, Chronic | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| AT-02 | AT-02 | Phase 2 Clinical | Attralus Inc | Immunoglobulin Light-chain Amyloidosis; Amyloidosis | Details |
| Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD) | Phase 1 Clinical | University Of California San Diego | Leukemia, Myeloid, Acute | Details | |
| AT-02 | AT-02 | Phase 2 Clinical | Attralus Inc | Immunoglobulin Light-chain Amyloidosis; Amyloidosis | Details |
| Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD) | Phase 1 Clinical | University Of California San Diego | Leukemia, Myeloid, Acute | Details |
This web search service is supported by Google Inc.
A-Z
